A Study of Intermittent Oral Dosing of ASP1517 in ESA-untreated Chronic Kidney Disease Patients With Anemia

Inclusion Criteria: * Subjects who were diagnosed with non-dialysis chronic kidney disease (CKD) and who are considered not to require renal replacement therapy during the study period * Mean of the subject's two most recent Hb values before randomization during the Screening Period must be \<10.5 g/dL with an absolute difference ≤1.3 g/dL between the two values * Either transferrin saturation ≥ 5% or serum ferritin ≥ 30 ng/mL * Female subject must either: Be of non-childbearing potential: * post-menopausal prior to pre-screening, or * documented surgically sterile Or, if of childbearing potential, * Agree not to try to become pregnant during the study after informed consent acquisition and for 28 days after the final study drug administration * And have a negative urine pregnancy test at pre-screening * And, if heterosexually active, agree to consistently use two forms of highly effective birth control (at least one of which must be a barrier method) starting at pre-screening and throughout the study period and for 28 days after the final study drug administration. * Female subject must agree not to breastfeed starting at pre-screening and throughout the study period, and for 28 days after the final study drug administration. * Female subject must not donate ova starting at pre-screening and throughout the study period, and for 28 days after the final study drug administration. * Male subject and their female spouse/partners who are of childbearing potential must be using…